Bionano Genomics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BNGO research report →
Range $1 – $175
Price Chart
About the company
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping.
- CEO
- Albert A. Luderer
- IPO
- 2018
- Employees
- 96
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on BNGO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $11.50M
- P/E
- -0.31
- Fwd P/E
- 4.11
- PEG
- -0.00
- P/S
- 0.37
- P/B
- 0.35
- EV/EBITDA
- -0.60
- Div Yield
- 0.00%
- Gross Margin
- 47.98%
- Op Margin
- -97.11%
- Net Margin
- -96.87%
- ROE
- -85.00%
- ROIC
- -86.63%
Latest fiscal year · YoY change
- Revenue
- $28.51M-7.4%
- Gross Profit
- $6.26M+1546.8%
- Op Income
- $-33,339,000
- Net Income
- $-26,395,000+76.4%
- EPS
- $-4.85+94.5%
- OCF Growth
- +76.3%
- FCF Growth
- +76.3%
- 52W High
- $2.23
- 52W Low
- $0.81
- 50D MA
- $1.33
- 200D MA
- $1.21
- Beta
- 1.71
- RSI (14)
- 26
- Avg Volume
- 979.44K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Bionano said Q3 revenue rose 12% as flow cell demand hit a record, while margins improved and management reiterated full-year 2026 revenue guidance.· November 10, 2026
- Q3 revenue was $8.3 million, up 12% year over year, with 9,870 flow cells sold, up 18% and a quarterly record.
- Adjusted gross margin improved to 48% from 46% a year ago, while operating expenses fell year over year.
- Consumables revenue grew 24% to $4.7 million, but software revenue fell 31% to $1.1 million on fewer VIA licenses.
- Management highlighted reimbursement progress, including MolDX’s proposed LCD and existing CPT codes/CMS rates for OGM.
- The company reiterated full-year 2026 revenue guidance of $31 million to $33 million and said it expects to land near the midpoint.
Revenue for Q3 2026 was $8.3 million, up 12% versus Q3 2025. Flow cells sold rose 18% year over year to 9,870 units, a record quarter. Adjusted gross margin was 48% versus 46% in the prior-year quarter. Adjusted operating expense was $8.8 million versus $9.7 million in Q3 2025, and operating expenses were $10.5 million, down 12% year over year. Cash, cash equivalents and available-for-sale securities ended at $8.7 million, including $0.5 million restricted. For full-year 2026, management reiterated revenue guidance of $31 million to $33 million, representing 9% to 16% growth over 2025, and said it expects to come in near the midpoint.
Albert Luderer framed the quarter as evidence that Bionano’s shift toward profitable growth with routine users is working. He emphasized that clinical adoption, reimbursement progress, and a growing evidence base are driving broader OGM utilization, and he pointed to MolDX, CPT coding, and new clinical site launches as important momentum builders. His tone was constructive and confident, with a repeated emphasis on 2027 EBITDA neutrality and a more profitable 2028.
Mark Adamchak focused on the financial profile improving through higher-margin consumables and tighter costs. He cited Q3 revenue of $8.3 million, adjusted gross margin of 48%, adjusted operating expense of $8.8 million, and quarter-end liquidity of $8.7 million in cash and available-for-sale securities, including $0.5 million restricted. He reiterated 2026 revenue guidance of $31 million to $33 million and said the company expects supply constraints to ease by year-end.
Analysts asked whether the earlier 2027 framework of $50 million to $54 million in revenue and near-breakeven adjusted EBITDA remains part of the operating plan. Management said the main focus for 2027 is EBITDA neutrality, supported by controlled expenses, rapid top-line growth, large customers coming online, and relief from supply constraints. Questions also centered on the drivers of higher flow-cell utilization and whether supply limits could temper growth; management pointed to strong clinical evidence, reimbursement coverage, and some sites becoming major users, while saying it expects to be free of back orders by year-end and to roughly double capacity by mid-2027. On Memorial Sloan Kettering, management said it was not ready to detail implementation specifics but expects adoption to take time and then progress into clinical service.
The quarter showed both top-line growth and better operating leverage, with record flow-cell sales, higher consumables revenue, and improved gross margin. Management also sees multiple demand catalysts in place: clinical evidence, reimbursement progress, and broader adoption at major cancer centers and existing routine users.
Software revenue declined 31% year over year, and management acknowledged that migrating array VIA customers to OGM will eventually reduce some software revenue before it is offset elsewhere. The balance sheet remains tight at $8.7 million in cash and securities, and management is still working through supply constraints tied to long-lead components before capacity fully catches up to demand.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 80.5%
- Shares Outstanding
- 13.98M
- Float Shares
- 11.25M
of shares held by institutions
33 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Aigh Capital Management LLC | 1.17M | ▲ 1.17M |
| Two Sigma Investments, LP | 483.56K | ▲ 483.56K |
| Renaissance Technologies LLC | 154.00K | ▲ 102.90K |
| Vanguard Capital Management LLC | 138.79K | ▲ 56.40K |
| Carret Asset Management, LLC | 135.54K | ▲ 10.54K |
| Hrt Financial LP | 96.87K | ▲ 85.13K |
| Gsa Capital Partners Llp | 92.38K | ▼ 57.90K |
| Acadian Asset Management LLC | 89.19K | ▲ 89.19K |
| Jane Street Group, LLC | 86.32K | ▲ 50.59K |
| Vanguard Group Inc | 82.31K | ▲ 31.85K |
| Geode Capital Management, LLC | 77.27K | ▼ 12.72K |
| Vanguard Fiduciary Trust Co | 51.58K | 0 |
Held by 7 ETFs
Biggest fund positions in BNGO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 4, 26 | Luderer Albert | buy | 4,000 |
| Aug 21, 26 | Luderer Albert | buy | 4,000 |
| Aug 3, 26 | Adamchak Mark | other | 5,000 |
| Aug 3, 26 | Dixon Jonathan V. | other | 15,000 |
| Aug 3, 26 | OLDAKOWSKI MARK | other | 15,000 |
| Aug 3, 26 | Hastie Alex Reid | other | 54,000 |
| Aug 3, 26 | OLDAKOWSKI MARK | other | 0 |
| Aug 3, 26 | Adamchak Mark | other | 0 |
| Aug 3, 26 | Hastie Alex Reid | other | 0 |
| Aug 3, 26 | Dixon Jonathan V. | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BNGO coverage
Recent articles, reports, and earnings notes.
No research on BNGO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BNGO report →Comparing Codexis (NASDAQ:CDXS) and Bionano Genomics (NASDAQ:BNGO)
defenseworld.net · Nov 11
Bionano Genomics, Inc. (BNGO) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
Bionano Reports Third Quarter 2026 Results and Provides a Business Update
globenewswire.com · Nov 10
Bionano to Report Third Quarter 2026 Financial Results and Host a Conference Call Webcast on November 10, 2026
globenewswire.com · Oct 27
Bionano Laboratories Announces Expansion of Diagnostic Testing Based on Optical Genome Mapping for Hematologic Malignancies
globenewswire.com · Sep 23
Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid Leukemia
globenewswire.com · Sep 14
Bionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic Neoplasms
globenewswire.com · Sep 10
Bionano Laboratories Announces New York State Department of Health Approval of Lab Developed Tests Based on Optical Genome Mapping
globenewswire.com · Sep 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.